Biotechnology

Servier Completes the Acquisition of Symphogen

PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including oncology. ...

2020-06-04 21:30 2747

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

AGC Biologics partners with Novavax to produce NVX-CoV2373 component SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner withNovavax, Inc. (NASDAQ: NVAX), a late-stage biot...

2020-06-03 19:00 3314

Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment

FREIBURG, Germany, June 3, 2020 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the co...

2020-06-03 10:00 1730

Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study

SUZHOU, China, June 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces...

2020-06-03 07:30 6882

Firmenich Appoints Boet Brinkgreve as President Ingredients

GENEVA, June 3, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...

2020-06-03 00:14 2661

Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services

Tigermed's comprehensive service portfolio and robust infrastructure cement its status as a strategic partner for the pharmaceuticals industry LONDON, June 2, 2020 /PRNewswire/ -- Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recogniz...

2020-06-02 22:00 6756

DERMALOG Fever Check at Clever Fit Gym

KALTENKIRCHEN and HAMBURG, Germany, June 2, 2020 /PRNewswire/ -- After a mandatory corona break of several weeks, sports facilities and fitness studios inGermany are reopening. Operators have to comply with numerous hygiene regulations to minimize infection risks for customers and employees. This...

2020-06-02 21:46 1918

Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India

WETTEREN, Belgium, June 2, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing ...

2020-06-02 20:04 2395

Cellenkos(R) Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome

HOUSTON, June 2, 2020 /PRNewswire/ -- Cellenkos Inc., a privately held, clinical stage biotech company announced today that the US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatmen...

2020-06-02 18:00 1803

Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

SUZHOU, China, June 2, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic,  autoimmune and other major diseases, announced the ...

2020-06-02 07:30 6277

AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings

AGC Biologics acquires Boulder, Colorado U.S.A. facility to increase global capacity and extend manufacturing scale SEATTLE, June 2, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the purchase of a state-of-the...

2020-06-02 06:00 3441

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most comm...

2020-06-01 08:45 5198

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced ...

2020-06-01 07:30 5304

Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TY...

2020-06-01 07:30 5409

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sin...

2020-06-01 07:30 5587

Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announce...

2020-06-01 07:30 5313

Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients

SINGAPORE, May 30, 2020 /PRNewswire/ -- According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on29 May 2020, researchers at Samsung Medical Center inSeoul, Korea, have found useful prognostic information beyond actionable biomarkers when the Guardant36...

2020-05-30 19:00 3447

Shinshu University and Toshiba Develop Tumor-Tropic Liposome Technology that Carries Therapeutic Genes into Cancer Cells

TOKYO, May 28, 2020 /PRNewswire/ -- Toshiba Corporation (TOKYO: 6502, hereinafter "Toshiba") and a team led by ProfessorYozo Nakazawa at the Department of Pediatrics, Shinshu University, (hereinafter "Shinshu University"), have together developed a "tumor-tropic liposome technology" for gene the...

2020-05-28 23:00 7926

CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2

LUXEMBOURG, May 28, 2020 /PRNewswire/ -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement withModerna, Inc. (Nasda...

2020-05-28 13:30 5858

WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories

SHANGHAI and NEW YORK, May 28, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized by Life Science Leader for the third year, achieving  2020 CMO Leadership Awards in six criter...

2020-05-28 08:00 2554
1 ... 171172173174175176177 ... 181